Retatrutide 20 mg + Tirzepatide 40 mg Complex

This dual-compound research formulation contains Retatrutide 20 mg + Tirzepatide 40 mg per 10 mL, combining two metabolic research compounds with distinct receptor activity profiles within a single experimental system.

Retatrutide is an investigational GIP, GLP-1, and glucagon receptor triple agonist studied in connection with multi-receptor signaling, energy metabolism, glucose homeostasis, and body-weight-related metabolic mechanisms.

Tirzepatide is a dual GIP/GLP-1 receptor agonist investigated in studies involving incretin signaling, glucose metabolism, insulin regulation, energy intake, and metabolic homeostasis.

As a combined research formulation, it may be used to investigate interactions among GLP-1, GIP, and glucagon receptor pathways and their relationships with glucose metabolism, energy balance, and metabolic regulation.

Although Tirzepatide is an active ingredient in approved medicines and Retatrutide is an investigational compound, this specific combination should not be considered an approved pharmaceutical product. The safety, efficacy, or appropriate dosing of the combination cannot be inferred from studies of either compound individually.

Livraison standard offerte dès 50 $ vers les États-Unis, le Canada, le Mexique et l'Europe. Expédition sous 1 jour ouvré.

Pas convaincu ? Renvoyez le produit sous 30 jours pour un remboursement intégral, même ouvert.